Waltham, United States
Zenas BioPharma, founded in 2020, is a clinical-stage global biopharmaceutical company headquartered in the United States. The company is devoted to transforming the lives of patients with autoimmune diseases, as encapsulated by its slogan: "Enabling patients with autoimmune diseases to reimagine life". Zenas focuses on developing and commercializing therapies with a strategy that uses their experienced leadership to strategically acquire and develop promising product candidates worldwide.
Their pipeline includes two late-stage potential franchise molecules: obexelimab and orelabrutinib. Obexelimab is a unique bifunctional monoclonal antibody targeting CD19 and FcγRIIb, aimed at inhibiting B cell activity in autoimmune diseases without depletion, while orelabrutinib is a selective CNS-penetrant BTK inhibitor tackling B cell-mediated inflammation in multiple sclerosis.
Zenas secured a substantial $200 Million in a Series C investment on 07 May 2024 from a consortium including Longitude Capital, Pivotal bioVenture Partners, Wellington Management, and others, reflecting strong investor confidence in their innovative approach and promising pipeline.
